Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
10 December 2018 | Story Leonie Bolleurs | Photo Leonie Bolleurs
One step closer to treat HIV/Aids
Nthabiseng Mokoena is working on an article based on her research about drug development in infection models, which will be published under the Research Chair in Pathogenic Yeasts.

South Africa has the biggest and most high-profile HIV epidemic in the world, with an estimated seven million people living with HIV in 2015. In the same year, there were 380 000 new infections while 180 000 South Africans died from AIDS-related illnesses. 

Invasive fungal infection, common in certain groups of patients with immune deficits, is a serious driver of global mortality in the context of the global HIV pandemic. 

“Despite a major scientific effort to find new cures and vaccines for HIV, hundreds of thousands of HIV-infected individuals continue to die on a yearly basis from secondary fungal infection. Intensive research needs to be done to help reduce the unacceptably high mortality rate due to the infection in South Africa,” said Nthabiseng Mokoena.

Mokoena is a master’s student of Prof Carlien Pohl-Albertyn, who is heading the Research Chair in Pathogenic Yeasts in the Department of Microbial, Biochemical and Food Biotechnology at the University of the Free State (UFS). 

She received her master’s degree at the December graduations of the UFS. Her thesis is titled: Caenorhabditis elegans as a model for Candida albicans-Pseudomonas aeruginosa co-infection and infection induced prostaglandin production.

Research Chair in Pathogenic Yeasts

Earlier this year, the National Research Foundation approved the Research Chair in Pathogenic Yeasts. One of the projects of the group of scientists in this chair include a study of the interaction between the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa in different hosts, using a variety of infection models.

In her research, Mokoena studied the response of infectious pathogens such as yeasts and bacteria, using a nematode (little roundworm) as an infection model to mimic the host environment. Nematodes have a number of traits similar to humans. It is thus a good alternative for humans as infection models, as it is unethical to use the latter.

Nematodes have a number of advantages, including its low cost and fast reproduction and growth. 

Mokoena monitored the survival of the nematodes to see how infectious the pathogens are, especially in combination with each other. 

Role of infection model for drug development

When these two pathogens were studied in a lab (in vitro), it was found that they can inhibit each other, but after studying them in the infection model (in vivo), Mokoena showed that these pathogens are more destructive together. 

This finding has a huge impact for the pharmaceutical industry, as it can provide information on how drugs need to be designed in order to fight infectious diseases where multiple organisms cause co-infections.

Many pathogens are resistant to drugs. Through this model, drugs can be tested in a space similar to the human body. Seeing how pathogens react to drugs within a space similar to the human body, can contribute to drug development. 

Not only are drugs developed more effectively through this model, it is also less expensive. 

It is the first time that the combination of the yeast, Candida albicans and the bacterium, Pseudomonas aeruginosa, is being experimented on in this model. 

News Archive

UFS study shows playing time in Super Rugby matches decreasing
2016-12-19

Description: Super Rugby playing time Tags: Super Rugby playing time 

The study by Riaan Schoeman, (left), Prof Robert Schall,
and Prof Derik Coetzee from the University of the Free State
on variables in Super Rugby can provide coaches with
insight on how to approach the game.
Photo: Anja Aucamp

It is better for Super Rugby teams not to have the ball, which also leads to reduced overall playing time in matches.

This observation is from a study by the University of the Free State on the difference between winning and losing teams. Statistics between 2011 and 2015 show that Super Rugby winning teams kick more and their defence is better.

These statistics were applied by Riaan Schoeman, lecturer in Exercise and Sport Sciences, Prof Derik Coetzee, Head of Department: Exercise and Sport Sciences, and Prof Robert Schall, Department of Mathematics and Actuarial Sciences. The purpose of the study, Changes in match variables for winning and losing teams in Super Rugby from 2011 to 2015, was to observe changes. Data on 30 games (four from each team) per season, supplied by the Cheetahs via Verusco TryMaker Pro, were used.

About two minutes less action
“We found that the playing time has decreased. This is the time the ball is in play during 80 minutes,” says Schoeman. In 2011, the average playing time was 34.12 minutes and in 2015 it was 31.95.

“The winning team has less possession of the ball and doesn’t want it. They play more conservatively. They dominate with kicks and then they play,” says Prof Coetzee, who was the conditioning coach for the Springboks in 2007 when they won the World Cup.

Lineouts also more about kicking
As a result, the number of line-outs also increased (from 0.31 per minute in 2011 to 0.34 in 2015) and the winning teams are better in this regard.

“The winning team has less possession of the ball
and doesn’t want it. They play a more conservative
game. They dominate with kicks and then they play.”

Schoeman believes that rule changes could also have contributed to reduced playing time, since something like scrum work nowadays causes more problems. “When a scrum falls, the time thereafter is not playing time.”

According to Prof Coetzee, rucks and mauls have also increased, (rucks from 2.08 per minute in 2011 to 2.16 in 2015 and mauls from 0.07 per minute in 2011 to 0.10 in 2015). “The teams that win, dominate these areas,” he says.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept